Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
Table 4
Summary of adverse events for patients with severe renal impairmenta.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Summary of adverse events for patients with severe renal impairmenta.